Dr. Glenn Dranoff became Global Head of Exploratory Immuno-oncology at Novartis on March 30, 2015. Before that he served as professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Dranoff developed a basic and translational research program to elucidate the cellular and molecular mechanisms underlying the generation of anti-tumor immunity. Work in his laboratory gave rise to multiple clinical protocols at the Dana-Farber Cancer Institute that have defined the biologic activity of several cancer immunotherapies in patients with solid or hematologic malignancies; these investigations have helped provide the foundation for the recent FDA approvals of the first therapeutic cancer vaccine and the first monoclonal antibody that blocks negative immune regulation.
Dr. Dranoff served as the leader of the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology, a co-leader of the Dana-Farber Cancer Vaccine Center, the director of the Dana-Farber Human Gene Transfer Laboratory, and the principal investigator of the Harvard Immunology Training Grant for Pre-doctoral Students in Cancer Immunology. He is the recipient of the Eli Lilly Biochemistry Award in Gene Therapy and the Stohler Scholarship of the Leukemia & Lymphoma Society, and was elected to the Academy of Cancer Immunology, the American Society of Clinical Investigation, the American Association of Physicians, the European Academy of Tumor Immunology, and the Osler Interurban Clinical Club. He is the Founding Editor-in-Chief of Cancer Immunology Research.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.